HAO revenueFY2026$54.83M
- FY YoY
- +67.1%
HAO revenue was $54.83M for fiscal 2026 (ended Jun 30, 2026), up 67.1% from fiscal 2025. It rose in 3 of the last 4 fiscal years. Fiscal 2026 is the highest of the 5 fiscal years on file.
Haoxi Health Technology Limited (HAO) financials
For fiscal 2026 (ended Jun 30, 2026), Haoxi Health Technology Limited reported $54.83M of revenue and -$9.54M of net income.
- Revenue, FY2026
- $54.83M
- Revenue growth, YoY
- +67.1%
- Net income, FY2026
- -$9.54M
- Net margin
- -17.4%
- EPS, diluted, FY2026
- -$386.40
- Cash
- $10.93M
- P/S
- 0.02
- Market cap
- $1.2M
FY2022FY2026
FY2022FY2026
FY2022FY2024
HAO revenue and earnings growth
HAO net incomeFY2026-$9.54M
HAO net income was -$9.54M for fiscal 2026 (ended Jun 30, 2026), compared with $3.88M in fiscal 2025.
HAO EPSFY2026-$386.40
HAO diluted EPS was -$386.40 for fiscal 2026 (ended Jun 30, 2026).
Income statement
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 |
|---|---|---|---|---|---|
| Revenue | $54.83M | $32.80M | $48.52M | $28.23M | $16.16M |
| Cost of revenue | $54.20M | $31.88M | $45.77M | $26.17M | $15.51M |
| Gross profit | $629.1K | $927.8K | $2.75M | $2.06M | $648.7K |
| Research and development | $104.4K | $79.5K | $80.0K | $58.2K | $102.5K |
| Selling, general and admin | $8.61M | $2.80M | $911.5K | $776.0K | $239.9K |
| Operating income | -$9.66M | -$2.00M | $1.72M | $1.20M | $268.8K |
| Interest expense | $52.4K | $46.0K | $41.2K | - | - |
| Pre-tax income | -$9.50M | $4.15M | $1.74M | $1.19M | $259.6K |
| Income tax | $36.6K | $270.7K | $443.6K | $220.7K | $15.0K |
| Net income | -$9.54M | $3.88M | $1.29M | $969.8K | $244.6K |
| EPS, basic | -$386.40 | $4251.81 | $2701.53 | $0.87 | $0.01 |
| EPS, diluted | -$386.40 | $3385.53 | $2701.53 | $0.87 | $0.01 |
| Diluted shares | 24,680 | 936 | 478 | 1.1M | 25.0M |
Balance sheet
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 |
|---|---|---|---|---|---|
| Cash and equivalents | $10.93M | $8.62M | $6.66M | $1.20M | $293.5K |
| Receivables | $5.9K | $460.3K | $226.7K | $7.7K | - |
| Current assets | $16.81M | $19.60M | $15.38M | $3.67M | - |
| Total assets | $21.57M | $21.60M | $15.51M | $4.46M | - |
| Current liabilities | $3.71M | $3.91M | $3.87M | $2.58M | - |
| Short-term debt | $290.7K | $300.3K | $833.5K | $27.3K | - |
| Long-term debt | - | $307.3K | $301.7K | $249.1K | - |
| Total debt | - | $607.7K | $1.14M | $276.5K | - |
| Total liabilities | $3.71M | $4.22M | $4.23M | $2.90M | - |
| Shareholders' equity | $17.86M | $17.38M | $11.27M | $1.57M | -$1.47M |
Cash flow
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 |
|---|---|---|---|---|---|
| Operating cash flow | -$2.57M | -$3.36M | -$747.6K | -$872.1K | -$675.4K |
| Capital expenditures | - | - | $55.4K | $45.5K | $8.7K |
| Free cash flow | - | - | -$802.9K | -$917.6K | -$684.1K |
| Investing cash flow | -$4.50M | -$3.58M | -$3.13M | -$45.5K | -$8.7K |
| Financing cash flow | $9.33M | $8.90M | $9.32M | $1.80M | $933.2K |
| Stock-based compensation | - | $58.6K | - | - | - |
| Depreciation and amortization | $308.6K | $294.6K | $10.6K | - | - |
Key ratios
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 |
|---|---|---|---|---|---|
| Revenue growth, YoY | 67.1% | -32.4% | 71.9% | 74.7% | - |
| Net income growth, YoY | - | 200.1% | 33.2% | 296.5% | - |
| Gross margin | 1.1% | 2.8% | 5.7% | 7.3% | 4.0% |
| Operating margin | -17.6% | -6.1% | 3.5% | 4.2% | 1.7% |
| Net margin | -17.4% | 11.8% | 2.7% | 3.4% | 1.5% |
| Free cash flow margin | - | - | -1.7% | -3.3% | -4.2% |
| Return on equity | -53.4% | 22.3% | 11.5% | 61.9% | - |
| Return on assets | -44.2% | 18.0% | 8.3% | 21.7% | - |
| Current ratio | 4.53 | 5.01 | 3.98 | 1.43 | - |
| Debt to equity | - | 0.03 | 0.10 | 0.18 | - |
Source: XBRL data Haoxi Health Technology Limited files with the SEC, latest filing dated Sep 30, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
HAO peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| HAO | $54.83M | +67.1% | -$9.54M | -17.4% | $1.2M |
| OMC | $24.76B | +54.1% | $704.90M | 2.8% | $23.57B |
| WPP | £13.55B | -8.1% | -£215.00M | -1.6% | $5.88B |
| STGW | $3.11B | +7.7% | $9.69M | 0.3% | $2.89B |
| IBTA | $357.74M | +1.6% | -$16.06M | -4.5% | $1.36B |
| CRTO | $1.81B | -7.5% | $77.95M | 4.3% | $758.9M |
| GRPN | $497.41M | +2.0% | -$125.66M | -25.3% | $629.7M |
| MNTN | $313.33M | +20.6% | $56.40M | 18.0% | $398.7M |
| ANGI | $968.94M | -8.4% | -$231.08M | -23.8% | $283.5M |
HAO FAQ
8 questionsWhat is HAO revenue?
Haoxi Health Technology Limited (HAO) reported $54.83M of revenue for fiscal 2026 (ended Jun 30, 2026). That is up 67.1% from the year before.Is HAO profitable?
No. Haoxi Health Technology Limited reported a net loss of $9.54M for fiscal 2026 (ended Jun 30, 2026).How much cash and debt does HAO have?
Haoxi Health Technology Limited reported $10.93M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is HAO revenue growing?
Haoxi Health Technology Limited's revenue changed +67.1% in fiscal 2026, to $54.83M.What is HAO gross margin?
Haoxi Health Technology Limited's gross profit was $629.1K on $54.83M of revenue for fiscal 2026 (ended Jun 30, 2026), a gross margin of 1.1%.What is HAO earnings per share?
Diluted earnings per share were -$386.40 for fiscal 2026 (ended Jun 30, 2026), from SEC filings, restated for any stock split those filings show.When did HAO last report financial results?
The latest statements here come from Haoxi Health Technology Limited's 20-F filed on Sep 30, 2026, covering the period ended Jun 30, 2026.Where does this HAO financial data come from?
Quantisnow builds these statements from the structured XBRL data Haoxi Health Technology Limited files with the SEC. It is provided for information only and is not investment advice.